Pulmonary Embolism Patients Fare Better At High-Volume Hospitals: Study
A new study finds that patients suffering from a pulmonary embolism have a better chance of survival if they go to a busy hospital.…
«
»
A new study finds that patients suffering from a pulmonary embolism have a better chance of survival if they go to a busy hospital.…
A new study warns that some melanoma drugs used in combination may increase the risk of serious heart problems.…
The FDA is warning that Pfizer’s ulcerative colitis drug, Xeljanz, could cause pulmonary embolism and deep vein thrombosis at higher doses.…
Side effects of the rheumatoid arthritis and ulcerative colitis drug Xeljanz may result in the development of serious and potentially lethal pulmonary embolism. Lawsuits are being reviewed by lawyers nationwide.…
A new study finds that early placement of IVC filters does not reduce the risk of pulmonary embolism or death in patients who have suffered severe trauma.…
European regulators have placed new restrictions on the use of Xeljanz while they continue to review potential pulmonary embolism risks.…
Xeljanz side effects may increase the risk of pulmonary embolism by a factor of five when taken at higher doses, according to the preliminary findings of a clinical trial.…
Pfizer is suing Ajanta Pharma over plans to release a generic version of Xeljanz years before its patent protection is scheduled to run out.…
Xeljanz side effects can cause pulmonary embolism at high doses, European drug regulators warn.…
Federal health officials indicate that side effects of Xeljanz, a popular rheumatoid arthritis and ulcerative colitis drug, may increase the risk of blood clots in the lungs, potentially resulting in a pulmonary embolism or death. The FDA’s Xeljanz warning was issued Monday, after a recent clinical trial found that patients taking certain dosage amounts of Xeljanz for rheumatoid arthritis were found to be more likely to develop blood clots or die, when compared to individuals taking the same doses of the drug to treat ulcerative colitis. Xeljanz (tofacitinib) is a drug that was first approved by the FDA in 2012…